TCR2 Therapeutics Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- TCR2 Therapeutics's estimated annual revenue is currently $4.5M per year.
- TCR2 Therapeutics received $125.0M in venture funding in March 2018.
- TCR2 Therapeutics's estimated revenue per employee is $42,009
- TCR2 Therapeutics's total funding is $269.5M.
- TCR2 Therapeutics has 107 Employees.
- TCR2 Therapeutics grew their employee count by 47% last year.
- TCR2 Therapeutics currently has 14 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Cell Signaling ...||$75.6M||577||N/A||N/A|
What Is TCR2 Therapeutics?
TCR2 is an innovative immunotherapy company developing the next generation of novel T cell receptor therapies for patients suffering from cancer.keywords:Biotechnology,Healthcare
Number of Employees
Employee Growth %
|Amy Lynch||Head Of Operations And Human Resources|
|Robert Hofmeister||Chief Scientific Officer||Email Available|
|Robert Tighe||Vp, Translational Research||Email Available|
|Seth Clarke||CMC Project Manager||Email Available|
|Peter Smith||Sr. Accounting Manager||Email Available|
|Andrew Cornforth||Vice-president Of Process Development||Email Available|
|Prakash Prabhakar||Sr. Director, Program Management & Clinical Operations|
|Kenanova Vania||Associate Director|
|Ian Hardy||Principal Scientist||Email Available|
TCR2 Therapeutics News
TCR2 Therapeutics has partnered with Raffit Hassan, MD, at the National Cancer Institute to test TC-210, a mesothelin-specific immunotherapy, ...
TCR² Therapeutics Inc. TCRR has been struggling lately, but the selling pressure may be coming to an end soon. That is because TCRR ...
If you want to know who really controls TCR2 Therapeutics Inc. (NASDAQ:TCRR), then you'll have to look at the makeup of its share registry.
TCR2 Therapeutics Funding
|2018-03-22||$125.0M||B||6 Dimensions Capital||Article|
TCR2 Therapeutics Executive Hires
|2017-10-12||Alfonso Cardama||Chief Medical Officer||Article|